Thought i might do some rather blatant ramping (sorry, but it...

Thought i might do some rather blatant ramping (sorry, but it is) by looking at QRXs potential revenues at certain sales volumes... feel free to chip in anyone.

What we know:
- tiered royalty on sales of 10, 20 and 30%
- 25% of remaining profits if QRX provides 25% of the selling capacity
Assume:
- sales force costs 30m per 60 people
- low costs to manufacture goods

While management are talking peak sales >US600m even sales of 250m result in about 60m in revenues to QRX. Assuming 30m pa for trials and general costs there should be enough to start paying a pretty good dividend. SRX are paying out about 5m in dividends currently and they have a MC of over 600m. If we get approval without damaging label restrictions, thats where QRS is headed in the next 2 to 3 years. But there is the matter of that FDA approval to get past first...